The first and only topical pain and wound management product for animals
Our quest is to enter the human market with our
leading pain mitigation and accelerated wound
healing platform technology.
Offering a patient focused solution to advance the standard of care for chronic and acute wounds, the technology has been developed as a topical “spray and stay” formulation providing several benefits when applied including pain relief, reduced bleeding and anti-bacterial activity.
Future near-term opportunities for the human proprietary product Medi-Solfen® include the treatment of traumatic wounds caused by surgical procedures, and mass trauma situations such as accidents, military conflict and natural disasters.
We are a life science development company
focused on mitigating pain and minimising suffering
from wounds, in humans
Team
Our mission
Medi-Solfen® has significantly reduced
commercialisation risks
Our story
Medi-Solfen Pty Ltd is an independent Australian life science company developing wound pain relief for humans.
Established by Medical Ethics Pty Ltd following the successful development and commercialisation of Tri-Solfen®, Medi-Solfen builds on a history of innovation in animal pain and wound care.
Medical Ethics pioneered the Solfen-Tech® platform, a patented topical technology developed to address pain and support wound management. Its first product, Tri-Solfen®, brought this approach to veterinary medicine, helping improve animal welfare by managing pain associated with wounds and surgical husbandry procedures.
The experience gained through Tri-Solfen’s development, regulatory approvals and commercialisation provided the foundation for establishing Medi-Solfen and advancing the technology for human applications.
Today, Medi-Solfen is taking that legacy forward through clinical development, with the goal of improving wound care and reducing pain and suffering for people.
Our Partners
